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Abstract  
Background: Major Depressive Disorder (MDD) is the second largest cause of global 
disease burden. It has an estimated heritability of 37% but published genome-wide 
association studies have so far identified few risk loci. Haplotype-block-based 
regional heritability mapping (HRHM) estimates the localized genetic variance 
explained by common variants within haplotype blocks, integrating the effects of 
multiple variants, and maybe more powerful for identifying MDD-associated genomic 
region.  
Methods: We applied HRHM to GS:SFHS, a large family and population based 
Scottish cohort (N=19,896). Single-SNP and haplotype-based association tests were 
used to localize the association signal within the regions identified by HRHM. 
Functional prediction was used to investigate the effect of MDD-associated SNPs 
within the regions. 
Results: A haplotype block across a 24kb region within the TOX2 gene reached 
genome-wide significance in HRHM. Single-SNP and haplotype-based association 
tests demonstrated that five out of nine genotyped SNPs and two haplotypes within 
this block were significantly associated with MDD. The expression of TOX2 and a 
brain-specific LncRNA RP1-269M15.3 in frontal cortex and Nucleus accumbens 
basal ganglia, respectively, were significantly regulated by MDD-associated SNPs 
within this region.  Both the regional heritability and single SNP-associations within 
this block were replicated in the UK-Ireland group of the most recent release of the 
Psychiatric Genomics consortium (PGC2-MDD). The SNP-association was also 
replicated in a depressive symptom sample that shares some individuals with PGC2-
MDD.  
Conclusion: This study highlights the value of HRHM for MDD and provides an 
important target within TOX2 for further functional studies.  
 
Key Words: Regional heritability; HRHM; TOX2; MDD; haplotype block; Genome-
wide analyses 
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Introduction 1 
Major Depressive Disorder (MDD) is ranked as the second leading contributor to the 2 
global disease burden in terms of the years lived with disability(1). The narrow sense 3 
heritability of MDD has been estimated to be approximately 37% by twin studies(2), 4 
suggesting a substantial contribution from genetic factors. In efforts to identify 5 
specific genetic risk factors for MDD, family-based linkage studies have identified 6 
several significant peaks in certain families, but the findings have been inconsistent(3). 7 
GWAS studies of unrelated participants have successfully identified hundreds of loci 8 
associated with other psychiatric disorders(4), but for MDD, only four genome-wide 9 
significant and replicable loci have been identified by two large GWAS studies, one 10 
on a refined MDD phenotype for Chinese Women and one on self-report-based 11 
depression using less intensive phenotyping in a much larger European sample(5-7).   12 
 13 
Several factors may be responsible for the comparatively sparse GWAS results in 14 
MDD. First, MDD is likely to have a highly polygenic genetic architecture where the 15 
disease risk is conferred by many causal variants of small effect(8,9). Combined with 16 
the high prevalence of MDD(10) and the possible incomplete LD between genotyped 17 
SNPs and causal SNPs, single-SNP based genome-wide association tests may have 18 
insufficient power to detect individual causal variants(11). Second, clinical 19 
heterogeneity has been shown in MDD between populations(6,12), and this may lead 20 
to difficulties in identifying causal variants across cohorts(13). Whilst GWAS sample 21 
sizes for MDD are increasing and efforts to refine MDD phenotype are in 22 
progress(5,7), alternative methodologies for detecting the signal arising from causal 23 
variants within and across families may also be productive.  24 
 25 
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Regional heritability mapping (RHM) is a method used to identify small genomic 26 
regions accounting for a significant proportion of the phenotypic variance in a trait of 27 
interest(14). In contrast to single-SNP based tests, RHM integrates effects from 28 
multiple SNPs by utilizing a regional genetic relationship matrix estimated from SNPs 29 
within a region. The matrix is constructed for each region defined by a sliding 30 
window across the genome, and is then used to estimate the variance explained by the 31 
variants within the region in a linear mixed model(14). The major advantage of RHM 32 
is that the regional genetic relationship matrices not only tag the effect of genotyped 33 
variants, but also measure the effect of un-genotyped and rare variants, including 34 
those associated with the SNPs but with individual effects too small to be detected by 35 
GWAS(14,15). Previous studies have shown that RHM has greater power to detect 36 
rare variants and multiple alleles in regions where GWASs provided null findings(15-37 
17). In 2014, Shirali .,et.al developed a haplotype-block-based heritability mapping 38 
(HRHM) method as an improved version of RHM. HRHM utilizes haplotype blocks 39 
as the unit of mapping therefore the identified blocks have less complex local LD 40 
structures(18).  41 
 42 
In this study, we applied HRHM to a homogenous sample of approximately 20K 43 
Scottish participants containing both closely- and distantly-related subjects with 44 
genome-wide genotyping data and a standardised structured clinical MDD 45 
diagnosis(19). We sought to identify genomic regions conferring risk for MDD, which 46 
were then further explored using single-SNP- and haplotype- based association tests. 47 
We then examined the functional effects of the MDD-associated SNPs within the 48 
identified block. Finally, replication analyses were performed in independent samples 49 
for both the regional heritability and SNP association results.  50 
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 51 
Methods and Materials 52 
The Tayside Research Ethics Committee (reference 05/S1401/89) provided ethical 53 
approval for the study. Participants all gave written consent, after having an 54 
opportunity to discuss the project, and before any data or samples were collected. 55 
 56 
Datasets 57 
Discovery sample: Generation Scotland: The Scottish Family Health Study (GS:SFHS) 58 
contains 21,387 subjects (Nmale=8,772, Nfemale=12,615; Agemean=47.2(SD=15.1)), who 59 
were recruited from the registers of collaborating general practices in Glasgow, 60 
Tayside,  Ayrshire, Arran and Northeast regions of Scotland. At least one first-degree 61 
relative aged 18 or over was required to be identified for each participant(19,20). A 62 
structured clinical interview was used for the diagnosis of lifetime DSM-IV mood 63 
disorders (SCID)(21,22). Details of MDD diagnosis, genotyping, quality control (QC) 64 
and imputation methods are described in Text s1. In total 561,125 genotyped and 65 
8,642,105 post-imputation autosomal SNPs passed QC criteria were available for 66 
19,896 participants (2,659 MDD cases and 17,237 controls) for subsequent analyses. 67 
 68 
Replication sample 1: UK Biobank 69 
Data used in this study were provided as part of UK Biobank project reference #4844. 70 
Details for genotyping, quality control, imputation and phenotyping are described in 71 
Text s2. In brief, genotyping data was available for 152,729 UK Biobank participants 72 
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recruited in United kingdom(23).  The probable MDD phenotype was created based 73 
on the putative MDD definition established in Smith et al(2013) using responses to a 74 
touchscreen questionnaire (UK Biobank 2011b)(24), from self-report information, and 75 
from inpatient records via linkage to hospital episode data(Text s2). After quality 76 
control and removing subjects who were in both GS:SFHS and UK Biobank datasets, 77 
and one of each pair of close relatives (relatedness > 0.05) of GS:SFSHS participants 78 
or the remained UK Biobank participants, 1,198,327 SNPs for 24,015 subjects with 79 
putative MDD phenotype available (8,143 cases and 15,872 controls) remained in 80 
downstream analyses.   81 
 82 
Replication sample2: PGC Major Depression Dataset (PGC2-MDD) 83 
The Psychiatric Genomics Consortium provided individual genotypes (best guess) of 84 
imputed SNPs for participants from 22 cohorts in PGC2-MDD(Table s1). All cases 85 
met DSM-IV criteria for life MDD, the majority of them were ascertained clinically. 86 
Most control samples were screened and participants with lifetime MDD were 87 
removed(Table s1).  Details for genotyping, quality control, imputation and 88 
phenotyping are described in Text s3. After quality control and removing subjects 89 
overlapped with GS:SFHS and UK Biobank dataset, 32,554 subjects of European 90 
ancestry (13,261 cases and 19,293 controls) were used in downstream analysis. 91 
Consistent with earlier work(25,26), we grouped the 22 cohorts into 7 groups based 92 
on the country of ancestor information for regional heritability analysis(Table s1). 93 
 94 
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Replication sample3:  Depressive symptom datasets (DS) (this sample contains 95 
overlapping individuals with replication sample 1 and 2) 96 
Okbay et.al(2016) carried out a GWAS meta-analysis (N = 180,866) on three samples 97 
using depressive symptoms as the trait of interest (27). The ascertained MDD 98 
diagnosis information was available for two samples (PGC1-MDD(Ncases = 9,240, 99 
Ncontrols = 9,519) and the Resource for Genetic Epidemiology Research on Aging 100 
(GERA, Ncases = 7,231, Ncontrols = 49,316))(27). For the third sample (UK Biobank (N 101 
= 105,739)), a continuous phenotype measuring the severity of depressive symptom 102 
had been created and used in the meta-analysis(27). Whilst this sample overlapped 103 
with the PGC2-MDD and UK Biobank samples, it provided results based upon a non-104 
diagnostic quantitative measure of depressive symptoms and involved another large 105 
cohort, GERA(27). 106 
 107 
Genome-wide haplotype-block-based Regional Heritability Mapping (HRHM) 108 
Regional heritability mapping (RHM) is a method for detecting localized genomic 109 
regions where genetic variants contribute significantly to the variation of phenotype 110 
of interest(14). As an improved version of RHM, HRHM divides the genome into 111 
haplotype-blocks, based on the recombination hotspots in the genome(18). Details of 112 
HRHM are described in Text s4. In brief, in GS:SFHS the genotyped SNPs were 113 
mapped to 49,637 haplotype-blocks across the genome and the regional heritability 114 
was estimated and tested for each of the haplotype-blocks. A standard ‘two-GRM’ 115 
model incorporates two genomic relationship matrices (GRM); a regional genomic 116 
relationship matrix (rGRM) estimated from SNPs in the haplotype block and a 117 
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complement genomic relationship matrix (cGRM) estimated from all SNPs that are 118 
not included in in the haplotype block. These GRMs were jointly fitted as random 119 
effects in LMM. Covariates fitted as fixed effects include age, age2, sex, 20 principal 120 
components. A Log likelihood ratio test (LRT) is applied to test the significance of 121 
random effect represented in rGRM by comparing a model with both cGRM and an 122 
rGRM fitted against a model including the cGRM but without an rGRM fitted. The 123 
genome-wide significance threshold for P values from LRT is 1.01x10-124 
6(NBonferroni=49,637). This two-GRM model, while providing an unbiased estimate of 125 
regional heritability, was highly computationally demanding. To improve the 126 
calculation efficiency, a pre-adjustment strategy was applied in the genome-wide 127 
HRHM (Text s4). For haplotype-blocks that exceeded the genome-wide significant 128 
threshold, we re-tested the block using the two-GRM model to provide an accurate 129 
estimation of regional heritability in the target block. All the analyses were performed 130 
in REACTA(14,28). According to the GCTA-GREML Power Calculator, this study is 131 
well-powered for the GREML-based SNP heritability analysis (99.88%)(29). 132 
 133 
Localized association tests for the significant haplotype block identified by 134 
HRHM in GS:SFHS 135 
HRHM identified a significant block chr20:42555671-42579473, we performed a 136 
series of association tests to localize the association signals within this block in 137 
GS:SFHS.  138 
1) Single-SNP-based association test for common SNPs within the identified 139 
haplotype-block.  140 
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Association tests were performed on genotyped and imputed common SNPs located 141 
in the significant haplotype-block chr20:42555671-42579473 using GCTA-MLMA 142 
(linear mixed model based association analysis)(30). The SNP effect was tested as a 143 
fixed effect, other covariates included age, age2, sex and 20 PCs. To prevent the 144 
estimates of SNP effects from being confounded by the polygenic component and 145 
family structure, cGRM and cGRMkin were fitted simultaneously as random effects in 146 
the model(31). cGRM (complement-snp-set GRM) was the genomic relationship 147 
created matrix using all of the genotyped SNPs excluding the SNPs in the hit block; 148 
cGRMkin was the kinship relationship matrix (representing pedigree-associated 149 
genetic variation). cGRMkin was created by setting elements in cGRM that were less 150 
than or equal to 0.05 to 0(31). The estimated fixed effect (on the linear scale) was 151 
transformed to logit and liability scale using Taylor series approximation(32). 152 
Bonferroni multiple-testing-correction was performed for the P values for each SNP.  153 
 154 
2) Single-haplotype-based association test 155 
Single-haplotype-based association tests were performed for the common haplotypes 156 
(Frequency≥0.01) derived from the nine genotyped common SNPs located in the 157 
significant haplotype-block chr20:42555671-42579473 using GCTA-MLMA(30) for 158 
the full dataset and an unrelated dataset, and using famLBL(33) for a subset 159 
consisting of case-parent trios in GS:SFHS. Details of single-haplotype-based 160 
association test are described in Text s5.  161 
 162 
Functional effects of MDD-associated-SNPs in the significant block 163 
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The significant haplotype-block chr20:42555671-42579473 is located in the intron 164 
region and a proportion of an adjacent exon of gene TOX2. To investigate the 165 
potential functional effects from variants within this block, we imputed the 9 166 
genotyped SNPs within this block to 53 common SNPs based on HRC reference, all 167 
of them are non-coding SNPs. We performed single-SNP-based association test for 168 
each of them with MDD using GCTA-MLMA (the same method for genotyped SNPs). 169 
This identified 38 imputed SNPs significantly associated with MDD. We then 170 
examined the functional role of the 38 SNPs using the following functional annotation 171 
tools and analyses: the potential to affect the binding of transcription factors in 172 
Regulomedb(34), Genome Wide Annotation of VAriants(GWAVA), Genomic 173 
Evolutionary Rate Profiling (GERP)(35), brain-tissue-specific allelic effect on gene-174 
expression(eQTL analysis) based on GTEX and BRAINEAC, and brain-tissue-175 
specific allelic effect on DNA methylation in CpG loci(meQTL analysis). Details of 176 
these tools and analyses are described in Text s6.  177 
 178 
Replication analysis 179 
Regional heritability in the significant block identified in GS:SFHS 180 
Individual genotypes in UKbiobank and PGC2-MDD(22 cohorts) were used to 181 
estimate the regional heritability of the target haplotype block in the two samples. The 182 
two-GRM model (rGRM+cGRM) was applied to provide accurate estimates. For 183 
PGC2-MDD, the regional heritability was estimated for each of the 7 groups defined 184 
based on country of ancestor (Table s1) as well as for the combined dataset. 185 
 186 
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Single-SNP based association test for the five significant SNPs(genotyped) within the 187 
significant block identified in GS:SFHS 188 
For UK Biobank the single-SNP-based association tests were performed using a 189 
logistic model in PLINK(36). Covariates included age, sex, centre, batch and 15 190 
principal components provided by UK Biobank. For PGC2-MDD the association test 191 
was performed using a logistic model for each individual cohort. Covariates include 192 
sex and 20 principal components (the age variable was not yet available for the full 193 
dataset at the time of this study). Meta-analysis was performed across all cohorts in 194 
each group to generate group-level association statistics. The meta-analysis was 195 
performed using the ‘metagen’ function in R package ‘meta’. For the DS sample the 196 
GWAS summary statistics were downloaded from the website of social science 197 
GWAS consortium (http://www.thessgac.org/#!data/kuzq8).  198 
 199 
Results 200 
Genome-wide Haplotype-block-based regional Heritability Mapping (HRHM) was 201 
carried out for 49,637 haplotype-blocks using 56,1125 genotyped common SNPs in 202 
GS:SFHS for MDD (Ncase=2,659, Ncontrol=17,237). The regional heritability from each 203 
haplotype-block was tested using a pre-adjusted-GRM strategy in the linear mixed 204 
model. The Manhattan plot and qqplot for the LRT are shown in Figure 1. One 205 
haplotype-block covering a 24kb region in the intron region and a proportion of an 206 
adjacent exon of gene TOX2 exceeded the genome-wide significant threshold 207 
(PBonf_threshold=1.01x10-6): hg19:chromosome20:42555671-42579473 (Plrt=8.86x10-7) 208 
(Figure 1). The two-GRM model confirmed the significance of this haplotype-block 209 
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(Plrt=5.6 x10-7) and the regional heritability (   ) was estimated to be 0.008(0.006).  210 
The regional heritability of this block was more significant in females MDD 211 
(   =0.009, se=0.007, Plrt=5.64x10-5, Ncase=1,893, Ncontrol=9,818) than in males MDD 212 
(    0.003, se=0.004, Plrt=0.02, Ncase=765, Ncontrol=7,420).  213 
 214 
We further performed a series of association tests to disentangle the signal detected by 215 
HRHM in the significant block. Using the single-SNP-based association test, five of 216 
the nine genotyped common SNPs within the hit block were significantly associated 217 
with MDD (Table 1, s2). The five significant SNPs were in high linkage 218 
disequilibrium (LD) with each other (Figure 1D) and their minor alleles showed a 219 
consistent negative effect on the risk of MDD with the odds ratio ranging from 0.785 220 
to 0.833(Table 1). Haplotype-based association tests for haplotypes derived from the 221 
nine SNPs showed that two out of the seven common haplotypes (frequency ≥ 0.01) 222 
were associated with MDD. One of these haplotypes contains the minor (protective) 223 
alleles of the five single-SNP-level significant SNPs and one contains the major (risk) 224 
alleles. The size and the direction of the effects of the two haplotypes were consistent 225 
with that estimated from the single-SNP based tests (odds ratio: 0.792 for the 226 
protective haplotype and 1.232 for the risk haplotype) (Table 2). Additional 227 
association tests on sub datasets (unrelated and case-parents-trio) showed that the risk 228 
haplotype was significantly associated with MDD in the unrelated dataset (Table s3), 229 
whereas the protective haplotype was significant in case-parents-trio dataset (Table 230 
s4).  231 
 232 
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The significant block overlapped with an enhancer active in multi-tissues and cell 233 
lines including astrocytes (Figure 2A)(37), and multiple alternative transcription start 234 
sites (TSSs) including a TSS primarily expressed in thalamus (the TSS labeled as 235 
‘p3@TOX2’ in Figure 2A)(37), suggesting a potential regulatory role. To link the 236 
association signal from single variants with the potentially functional effects of those 237 
variants on disease-relevant biological processes, we identified 38 imputed SNPs in 238 
the target block significantly associated with MDD (Table s5), and predicted their 239 
potentially regulatory function using multiple predictors and statistics of non-coding 240 
DNA function, including the likelihood of affecting transcription factor binding, 241 
multi-genome-wide properties, evolutionary conservation, the cis-effect on gene 242 
expression of genes within a distance of 1MB and on DNA methylation. Among the 243 
38 SNPs, two of them were annotated to be ‘likely to affect TF binding’ (score=2b) by 244 
regulomeDB, five obtained a GWAVA-TSS score  ≥ 0.5 (suggesting ‘functional’) and 245 
five obtained a GERP-score >2 (suggesting ‘constrained’) (Table s6). Tissue-specific 246 
snp-cis-gene-expression (cis-eQTL) analyses were performed for the 38 SNPs using 247 
11 brain tissues from GTEX and 10 brain tissues from BRAINEAC. The results from 248 
GTEX showed that the genotype of 30 of the 38 SNPs significantly stratify the 249 
expression of gene RP1-269M15.3 (LncRNA) in the tissue ‘Nucleus accumbens basal 250 
ganglia’ with the minor alleles significantly up-regulating the RNA expression level 251 
(Table s7)(Figure 2B). The results from BRAINEAC suggested that all of the 38 252 
SNPs significantly stratify the expression of gene TOX2 in frontal cortex (minor allele 253 
induces up-regulation) (Figure 2C) and gene C20orf62 (LncRNA) (minor allele 254 
induces down-regulation) in Cerebellar cortex (Table s8,s9). The results from meQTL 255 
analysis suggested that 30 of the 38 SNPs are significant meQTL SNPs in frontal 256 
cortex, and that particularly 19 of them significantly stratify DNA methylation of a 257 
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CpG locus cg24403644 (minor allele induces hypo-methylation) (Table s10).  258 
cg24403644 is located in a cluster of TSSs in TOX2 (Figure 2) and shows differential 259 
methylation between human fetal and postnatal lifetime in frontal cortex and during 260 
the fetal brain development(38,39). Among significant SNPs in the cis-eQTL and cis-261 
meQTL analyses, rs79645278 located in the peak of active enhancer (in astrocytes 262 
and other cell lines), and was predicted to be ‘likely to affect TF binding’ (2b) in 263 
RegulomeDB, having a GWAVA-TSS score of 0.5 and a GERP-score of 2.31(Figure 264 
2A,B,C, Table s6).  265 
 266 
The regional heritability detected in the hit block was replicated in the UK-Ireland 267 
group in PGC2-MDD with nominal significance (Plrt=0.049,    =0.001,se=0.001), 268 
whilst it was not significant in other groups in PGC2-MDD and UK Biobank (Table 269 
s11). The single-SNP-based association test for the five significant SNPs (genotyped) 270 
in this block identified in GS:SFHS showed that all five were replicated in the DS 271 
sample; all five were also replicated in the UK-Ireland group in PGC2-MDD (Table 1. 272 
Results for individual cohorts were shown in Table s12 and Figure s1), but not in 273 
other PGC2-MDD groups or in the meta-analysed combined PGC2-MDD sample 274 
(Table s13); none of the five SNPs were replicated in the UK Biobank sample but all 275 
showed the same consistent direction of effect with that reported in the discovery 276 
sample (Table 1, Figure s1). Meta-analysis using all independent UK-Ireland 277 
replication samples (UK Biobank + 4 cohorts in PGC2-MDD-UK_Ireland) showed 278 
that all of the five SNPs reached nominal significance (Table s13, consistent sign with 279 
GS:SFHS as shown in Figure 3, using SNP rs6093898 as an example.  280 
 281 
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Discussion 282 
The current study used a combination of genome-wide haplotype-block-based 283 
regional heritability mapping (HRHM), localized association tests and functional 284 
prediction to identify candidate genomic region associated with MDD. Using a large 285 
Scottish cohort GS:SFHS, a genome-wide significant haplotype block located in gene 286 
TOX2 was identified by HRHM as a risk region for MDD. Association tests using 287 
both single SNPs and haplotypes within this block highlighted candidate contributing 288 
genetic variants for MDD. Replication analyses showed that the regional heritability 289 
in this block was nominally significant in the UK-Ireland groups in PGC2-MDD. The 290 
SNP-level association signals within the hit block were replicated in the UK-Ireland 291 
group in PGC2-MDD and a study of depressive symptom (DS) which has overlapping 292 
subjects from PGC2-MDD and UK Biobank. 293 
 294 
As shown in this study, compared with single-SNP-based genome-wide association 295 
methods (GWAS), HRHM provided following advantages: (1) a smaller number of 296 
tests were performed therefore a less stringent threshold of genome-wide significance 297 
was applied. (2) Haplotype blocks rather than single SNPs were the unit of mapping, 298 
these are therefore relatively less dependent on the density of the genotype arrays and 299 
do not require the same SNPs to be typed or imputed in replication study. (3) HRHM 300 
applied a linear mixed model accounting for both polygenic component and family 301 
structure, and can be applied to both population and family data. (4) Since haplotype 302 
blocks were used as the unit of mapping, the identified locus has a less complex LD 303 
structure (Figure 1D), which will benefit the downstream identification of candidate 304 
variants.  305 
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 306 
To date, published GWASs have mapped associated variants to very few genes for 307 
MDD (LHPP, SIRT1, TMEM161B–MEF2C and NEGR1)(5,7). In this study, the 308 
identified haplotype block was located in gene TOX2 (TOX high mobility group box 309 
family member 2, also known as GCX1), indicating a new candidate gene for MDD. 310 
TOX2 is a putative transcriptional activator involved in the hypothalamo-pituitary-311 
gonadal system(40), and is located in a large genomic region which has been 312 
previously reported as associated with depression symptoms in psychotic 313 
illness(41,42). The same locus has also been weakly-associated with conduct disorder 314 
in a previous study(43). Using available databases, we found that convergent evidence 315 
from TSS by Fantom5 annotation (Figure 2A), histone modification markers and 316 
Dnase peaks representing active enhancers by ENCODE annotation (Figure 2A), and 317 
transcription factor binding prediction by RegulomeDB (Table s6) suggested a 318 
regulatory function of this block. To test for the potential effects of the variants within 319 
the block on gene expression, we performed brain-tissue specific cis-QTL analysis for 320 
SNPs significantly associated with MDD within the block. The expression of a 321 
LncRNA RP1-269M15.3 was significantly up-regulated by the minor alleles (minor 322 
alleles are protective to MDD as shown in Table 1, s5) of candidate SNPs within the 323 
block in Nucleus Accumbens, a tissue having been previously implicated in MDD(44). 324 
RP1-269M15.3 was a multi-exon LncRNA with a multi-species conserved region 325 
(Figure s2A) and was only expressed specifically in brain tissues (Figure s2B) and 326 
therefore of potential function in brain tissues. Similarly, the expression of gene TOX2 327 
was significantly up-regulated by the minor alleles of candidate SNPs in frontal 328 
cortex, a relevant tissue of MDD as well (45). The regulatory effect of MDD-329 
associated SNPs in gene TOX2 in frontal cortex is further supported by the meQTL 330 
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analysis on the same tissue. Combined with the fact that all of the 19 SNPs are both 331 
meQTL and eQTL SNPs for gene TOX2 in frontal cortex and the fact that hypo-332 
methylation has been previously suggested to be correlated with up-regulation of gene 333 
expression(46), consistent evidence from both methylation and gene expression data 334 
indicated that the minor alleles (protective) of MDD-associated SNPs up-regulate the 335 
gene expression of TOX2 in frontal cortex(Table s8,s10).  Interestingly, the brain-336 
specific expression of both RP1-269M15.3 and TOX2 were highly correlated (r ≥ 0.7) 337 
with a number of depression-related genes (for example, LRFN5, GRM7, CRH)(47,48) 338 
in brain development (http://brainspan.org) (Table s14, s15), suggesting that the 339 
expression networks involving those genes were potential targets of the effects from 340 
candidate variants. These results are consistent with a previous study suggesting an 341 
overrepresentation of MDD GWAS significant loci in CNS expression and the 342 
regulation of gene expression in CNS during development(7).  343 
 344 
The regional heritability in the identified block was nominally significant only in the 345 
UK-Ireland group of PGC2-MDD. The five significant genotyped SNPs within the 346 
block identified in GS:SFHS were replicated in DS sample and in the UK-Ireland 347 
group in PGC2-MDD. UK Biobank sample failed to replicate any of them, although 348 
they showed consistent sign of effect. Those results are likely attributable to the 349 
phenotyping differences (diagnosed MDD in GS:SFHS, mostly diagnosed MDD in 350 
PGC(49), putative MDD in UK Biobank and depressive symptom in DS), and the 351 
clinical heterogeneity within MDD across PGC2-MDD groups as shown in Table 352 
s10)(12). Notably, UK-Ireland which shows the most consistent replication results are 353 
from the same country/region with GS:SFHS, so its cohorts are likely to have a 354 
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similar local genomic recombination pattern and LD structure with GS:SFHS and 355 
potentially carry alleles not common in other European cohorts, which may explain 356 
the better replication result from this group (Figure 3,s1).   357 
 358 
There are, however, several limitations in the current study. Firstly, the re-adjustment 359 
strategy applied to genome-wide HRHM, whilst it reduced the computational burden, 360 
it was potentially excessively conservative in reporting true associations (observed 361 
LRT statistics were depleted from expectation, as shown in Figure 1D), which 362 
consequently reduced the power of HRHM(50). Secondly, phenotypic difference 363 
among discovery and replication samples impeded the complete replication of 364 
findings across all samples. UK Biobank samples are also from the same 365 
country/region as GS:SFHS, as are the UK-Ireland group of PGC2-MDD, but 366 
currently UK Biobank only have putative MDD information available for a small 367 
subset of genotyped participants. Ongoing clinical assessment of MDD and the 368 
genotyping work on this sample will potentially provide more power to the replication 369 
analysis for our findings in future data releases.  370 
 371 
Conclusion 372 
The present study showed the first application of genome-wide HRHM to a 373 
psychiatric disorder. A genome-wide significant region was identified by HRHM and 374 
the contributing genetic effect was localized to variants and haplotypes within the 375 
block. The results were partly replicated in two independent samples. Functional 376 
prediction and cis-eQTL analyses suggested that the genotype of associated-variants 377 
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within the block stratified the gene expression of a potentially functional LncRNA 378 
RP1-269M15.3 and gene TOX2 in MDD-relevant brain tissues, which should be 379 
explored in further studies. 380 
 381 
Data Access: 382 
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Legends 442 
Table 1. Single-SNP-based association test results for five MDD-associated SNPs in 443 
discovery and replication samples. 444 
 445 
Table 2 Haplotype-based association test results for common haplotypes derived from 446 
the nine genotyped common SNPs in GS:SFHS. 447 
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Adjusted P:  Bonferroni method adjusted P values. 448 
 449 
Figure 1 Genome-wide haplotype-block-based regional heritability mapping(HRHM) 450 
results on MDD in GS:SFHS. A: Manhattan plot. Each point represents a haplotype 451 
block. The location of the point is the mid-position of the haplotype block. B: qqplot 452 
for the LRT. The LRT statistics distributed as a mixture of 0 and chi-squared (df=1) 453 
distribution. C: zoom in region of the hit haplotype block region in Chromosome 20. 454 
D: LD structure within the hit haplotype block in GS:SFHS. The block is located in 455 
gene TOX2, it contains nine genotyped common SNPs(blue box) and five of them are 456 
in high LD(red arrow) in GS:SFHS. 457 
 458 
Figure 2 Functional prediction of the hit haplotype block. A: functional annotation of 459 
the hit block. The hit haplotype block (red bar on the left top showing the block and 460 
blue bars showing the genotype SNPs in GS:SFHS) is located in the intron region and 461 
a proportion of an adjacent exon of gene TOX2, overlapped with Fantom5 enhancers 462 
and Transcription start sites, and regulatory-relevant histone modification 463 
peaks(H3K27Ac and H3K4Me1). Within the block, 38 imputed SNPs were associated 464 
with MDD, using SNP rs79645278(pink) as an example. This SNP is located in the 465 
peak of active enhancer in astrocyte(highlighted with blue line). B,C: boxplots 466 
showing tissue specific effect from SNPs that are both associated with MDD in 467 
GS:SFHS and gene expression, using SNP rs79645278 as an example. B: the minor 468 
allele of rs79645278 up-regulates the expression of a LncRNA RP1-269M15.3 in the 469 
tissue ‘Nucleus accumbens basal ganglia’. C: the minor allele of rs79645278 up-470 
regulates the expression of gene TOX2 in Frontal cortex. Abbreviations: cerebellar 471 
cortex (CRBL), frontal cortex (FCTX), hippocampus (HIPP), medulla (specifically 472 
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inferior olivary nucleus, MEDU), occipital cortex (specifically primary visual cortex, 473 
OCTX), putamen (PUTM), substantia nigra (SNIG), thalamus (THAL), temporal 474 
cortex (TCTX) and intralobular white matter (WHMT). 475 
 476 
Figure 3 Forest plot showing meta-analysis for single-SNP-based association test on 477 
GS:SFHS and all UK/Ireland replication samples(four PGC2-MDD cohorts and UK 478 
biobank), using SNP rs6093898 as an example. 479 
 480 
 481 
Yanni Zeng    
 24 
Reference 482 
1. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ, et al. 483 (2013) Burden of depressive disorders by country, sex, age, and year: 484 findings from the global burden of disease study 2010. PLoS Med 10: 485 e1001547. 486 2. Sullivan PF, Neale MC, Kendler KS (2000) Genetic epidemiology of major 487 depression: review and meta-analysis. Am J Psychiatry 157: 1552-1562. 488 3. Lohoff FW (2010) Overview of the genetics of major depressive disorder. Curr 489 Psychiatry Rep 12: 539-546. 490 4. Schizophrenia Working Group of the Psychiatric Genomics C (2014) Biological 491 insights from 108 schizophrenia-associated genetic loci. Nature 511: 421-492 427. 493 5. consortium C (2015) Sparse whole-genome sequencing identifies two loci for 494 major depressive disorder. Nature 523: 588-591. 495 6. Major Depressive Disorder Working Group of the Psychiatric GC, Ripke S, Wray 496 NR, Lewis CM, Hamilton SP, Weissman MM, et al. (2013) A mega-analysis 497 of genome-wide association studies for major depressive disorder. Mol 498 Psychiatry 18: 497-511. 499 7. Hyde CL, Nagle MW, Tian C, Chen X, Paciga SA, Wendland JR, et al. (2016) 500 Identification of 15 genetic loci associated with risk of major depression 501 in individuals of European descent. Nat Genet advance online publication. 502 8. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, et al. 503 (2009) Potential etiologic and functional implications of genome-wide 504 association loci for human diseases and traits. Proceedings of the National 505 Academy of Sciences of the United States of America 106: 9362-9367. 506 9. Moser G, Lee SH, Hayes BJ, Goddard ME, Wray NR, Visscher PM (2015) 507 Simultaneous discovery, estimation and prediction analysis of complex 508 traits using a bayesian mixture model. PLoS Genet 11: e1004969. 509 10. Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. 510 (2011) Cross-national epidemiology of DSM-IV major depressive episode. 511 BMC Med 9: 90. 512 11. Flint J, Kendler KS (2014) The genetics of major depression. Neuron 81: 484-513 503. 514 12. Milaneschi Y, Lamers F, Peyrot WJ, Abdellaoui A, Willemsen G, Hottenga JJ, et 515 al. (2015) Polygenic dissection of major depression clinical heterogeneity. 516 Mol Psychiatry. 517 13. Wray NR, Maier R (2014) Genetic Basis of Complex Genetic Disease: The 518 Contribution of Disease Heterogeneity to Missing Heritability. Current 519 Epidemiology Reports 1: 220-227. 520 14. Nagamine Y, Pong-Wong R, Navarro P, Vitart V, Hayward C, Rudan I, et al. 521 (2012) Localising loci underlying complex trait variation using Regional 522 Genomic Relationship Mapping. PLoS One 7: e46501. 523 15. Uemoto Y, Pong-Wong R, Navarro P, Vitart V, Hayward C, Wilson JF, et al. 524 (2013) The power of regional heritability analysis for rare and common 525 variant detection: simulations and application to eye biometrical traits. 526 Front Genet 4: 232. 527 16. Riggio V, Matika O, Pong-Wong R, Stear MJ, Bishop SC (2013) Genome-wide 528 
Yanni Zeng    
 25 
association and regional heritability mapping to identify loci underlying 529 variation in nematode resistance and body weight in Scottish Blackface 530 lambs. Heredity (Edinb) 110: 420-429. 531 17. Shirali M, Pong-Wong R, Navarro P, Knott S, Hayward C, Vitart V, et al. (2016) 532 Regional heritability mapping method helps explain missing heritability 533 of blood lipid traits in isolated populations. Heredity (Edinb) 116: 333-534 338. 535 18. Shirali M. Using Haplotype Mapping to Uncover the Missing Heritability: A 536 Simulation Study; 2014. Asas. 537 19. Smith BH, Campbell H, Blackwood D, Connell J, Connor M, Deary IJ, et al. 538 (2006) Generation Scotland: the Scottish Family Health Study; a new 539 resource for researching genes and heritability. BMC Med Genet 7: 74. 540 20. Smith BH, Campbell A, Linksted P, Fitzpatrick B, Jackson C, Kerr SM, et al. 541 (2013) Cohort Profile: Generation Scotland: Scottish Family Health Study 542 (GS:SFHS). The study, its participants and their potential for genetic 543 research on health and illness. International Journal of Epidemiology 42: 544 689-700. 545 21. First MB, Spitzer RL, Gibbon M, Williams JB (2001) Structured clinical 546 interview for DSM-IV-TR axis I disorders—non-patient edition. New York 547 State Psychiatric Institute, New York. 548 22. Fernandez-Pujals AM, Adams MJ, Thomson P, McKechanie AG, Blackwood DH, 549 Smith BH, et al. (2015) Epidemiology and Heritability of Major Depressive 550 Disorder, Stratified by Age of Onset, Sex, and Illness Course in Generation 551 Scotland: Scottish Family Health Study (GS:SFHS). PLoS One 10: e0142197. 552 23. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. (2015) UK 553 biobank: an open access resource for identifying the causes of a wide 554 range of complex diseases of middle and old age. PLoS Med 12: e1001779. 555 24. Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J, et al. (2013) 556 Prevalence and characteristics of probable major depression and bipolar 557 disorder within UK biobank: cross-sectional study of 172,751 participants. 558 PLoS One 8: e75362. 559 25. Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, et al. (2013) 560 Genetic relationship between five psychiatric disorders estimated from 561 genome-wide SNPs. Nature Genetics 45: 984-+. 562 26. Zeng Y, Navarro P, Fernandez-Pujals AM, Hall LS, Clarke T-K, Thomson PA, et 563 al. (2016) A Combined Pathway and Regional Heritability Analysis 564 Indicates NETRIN1 Pathway is Associated with Major Depressive Disorder. 565 Biological Psychiatry. 566 27. Okbay A, Baselmans BM, De Neve JE, Turley P, Nivard MG, Fontana MA, et al. 567 (2016) Genetic variants associated with subjective well-being, depressive 568 symptoms, and neuroticism identified through genome-wide analyses. 569 Nat Genet. 570 28. Cebamanos L, Gray A, Stewart I, Tenesa A (2014) Regional heritability 571 advanced complex trait analysis for GPU and traditional parallel 572 architectures. Bioinformatics 30: 1177-1179. 573 29. Visscher PM, Hemani G, Vinkhuyzen AA, Chen GB, Lee SH, Wray NR, et al. 574 (2014) Statistical power to detect genetic (co)variance of complex traits 575 using SNP data in unrelated samples. PLoS Genet 10: e1004269. 576 30. Yang J, Lee SH, Goddard ME, Visscher PM (2011) GCTA: a tool for genome-577 
Yanni Zeng    
 26 
wide complex trait analysis. Am J Hum Genet 88: 76-82. 578 31. Zaitlen N, Kraft P, Patterson N, Pasaniuc B, Bhatia G, Pollack S, et al. (2013) 579 Using Extended Genealogy to Estimate Components of Heritability for 23 580 Quantitative and Dichotomous Traits. Plos Genetics 9. 581 32. Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, Leo P, et al. (2013) 582 Identification of multiple risk variants for ankylosing spondylitis through 583 high-density genotyping of immune-related loci. Nature Genetics 45: 730-584 +. 585 33. Wang M, Lin SL (2014) FamLBL: detecting rare haplotype disease association 586 based on common SNPs using case-parent triads. Bioinformatics 30: 587 2611-2618. 588 34. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al. 589 (2012) Annotation of functional variation in personal genomes using 590 RegulomeDB. Genome Res 22: 1790-1797. 591 35. Davydov EV, Goode DL, Sirota M, Cooper GM, Sidow A, Batzoglou S (2010) 592 Identifying a High Fraction of the Human Genome to be under Selective 593 Constraint Using GERP plus. Plos Computational Biology 6. 594 36. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. 595 (2007) PLINK: a tool set for whole-genome association and population-596 based linkage analyses. Am J Hum Genet 81: 559-575. 597 37. Lizio M, Harshbarger J, Shimoji H, Severin J, Kasukawa T, Sahin S, et al. (2015) 598 Gateways to the FANTOM5 promoter level mammalian expression atlas. 599 Genome Biol 16: 22. 600 38. Jaffe AE, Gao Y, Deep-Soboslay A, Tao R, Hyde TM, Weinberger DR, et al. (2016) 601 Mapping DNA methylation across development, genotype and 602 schizophrenia in the human frontal cortex. Nat Neurosci 19: 40-47. 603 39. Spiers H, Hannon E, Schalkwyk LC, Smith R, Wong CC, O'Donovan MC, et al. 604 (2015) Methylomic trajectories across human fetal brain development. 605 Genome Res 25: 338-352. 606 40. Kajitani T, Mizutani T, Yamada K, Yazawa T, Sekiguchi T, Yoshino M, et al. 607 (2004) Cloning and characterization of granulosa cell High-Mobility group 608 (HMG)-box-protein-1, a novel HMG-box transcriptional regulator strongly 609 expressed in rat ovarian granulosa cells. Endocrinology 145: 2307-2318. 610 41. Zhang XY, Bigdeli TB, Maher BS, Zhao Z, van den Oord EJCG, Thiselton DL, et al. 611 (2011) Comprehensive Gene-Based Association Study of a Chromosome 612 20 Linked Region Implicates Novel Risk Loci for Depressive Symptoms in 613 Psychotic Illness. PLoS ONE 6: e21440. 614 42. Fanous AH, Neale MC, Webb BT, Straub RE, O'Neill FA, Walsh D, et al. (2008) 615 Novel linkage to chromosome 20p using latent classes of psychotic illness 616 in 270 Irish high-density families. Biological Psychiatry 64: 121-127. 617 43. Dick DM, Aliev F, Krueger RF, Edwards A, Agrawal A, Lynskey M, et al. (2011) 618 Genome-wide association study of conduct disorder symptomatology. Mol 619 Psychiatry 16: 800-808. 620 44. Pizzagalli DA, Holmes AJ, Dillon DG, Goetz EL, Birk JL, Bogdan R, et al. (2009) 621 Reduced caudate and nucleus accumbens response to rewards in 622 unmedicated individuals with major depressive disorder. Am J Psychiatry 623 166: 702-710. 624 45. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M, Lewis 625 DA, et al. (2011) Altered expression of genes involved in inflammation and 626 
Yanni Zeng    
 27 






















































































































































































 Table 1. Single-SN













































































































































 Table 2 H
aplotype-based association test results for com
m
on haplotypes derived from







djusted P:  B
onferroni  m
ethod adjusted P values. 
Table 2
















































































Genome-wide regional heritability mapping identifies a locus within the TOX2 gene associated with 
Major Depressive Disorder 
Text s1. Genotyping, quality control, imputation and phenotyping details in GS:SFHS dataset. 
Text s2. Genotyping, quality control, imputation and phenotyping details in UK Biobank dataset. 
Text s3. Genotyping, quality control, imputation and phenotyping details in PGC2-MDD dataset. 
Text s4. Genome-wide haplotype-block-based Regional Heritability Mapping (HRHM) 
Text s5. Single-haplotype-based association test. 
Text s6. Functional annotation tools and analyses for MDD-associated SNPs.  
Table s1. Individual cohort and grouping information for 22 cohorts in PGC2-MDD. 
Table s2 Single-SNP based association test results for nine genotyped SNPs in the hit haplotype block in GS:SFHS. 
Table s3 Haplotype-based association test results for common haplotypes derived from nine common SNPs in hit 
block on unrelated individual dataset of GS:SFHS.     
Table s4 Haplotype-based association test results for common haplotypes derived from nine common SNPs in hit 
block on case-parents-trio of GS:SFHS. 
Table s5 Results of Single-SNP based association test on 53 imputed common SNPs in the hit block in GS:SFHS. 
Table s6 The functional prediction of 38 significant SNPs using regulomeDB score, GWAVA-Tss score and GERP 
score. 
Table s7 Significant results (Q value ≤ 0.05) from SNP-cis-gene-eQTL analysis using GTEX. 
Table s8 Significant results (Q value ≤ 0.05) from SNP-cis-gene-eQTL analysis on Frontal cortex using BRAINEAC. 
Table s9 Significant results (Q value ≤ 0.05) from SNP-cis-gene-eQTL analysis on Cerebellar cortex using 
BRAINEAC. 
Table s10 Significant results of meQTL SNPs for CpG locus cg24403644 (FDR ≤ 0.05) from SNP-cis-CpG DNA 
methylation analysis on Frontal cortex.  
Table s11 Regional heritability estimates of the hit block in seven groups and the combined (22 cohorts) in PGC2-
MDD and UK Biobank. 
Table s12 Single-SNP-based association tests for five SNPs in individual cohorts PGC2-MDD. 
Table s13 Meta-analysis results for five SNPs in groups and combined sample of PGC and all UK replication samples. 
Table s14 Genes showing similar expression patterns with RP1-269M15.3 (r≥0.7) in development brain tissues in 
BRAINSPAN. 
Table s15 Genes showing similar expression patterns with TOX2 (r≥0.7) in development brain tissues in 
BRAINSPAN. 
Figure s1 Forest plots of meta-analysis of GS:SFHS, PGC2-MDD individual cohorts and UK Biobank for five SNPs. 
Figure s2 Functional annotation and gene expression patterns of RP1-269M15.3. 
Supplemental Information
Click here to download Supplemental Information: supple_MDD_HRHM_15-11-2016.docx
Yanni Zeng            
 
 2 
Text s1. Genotyping, quality control, imputation and phenotyping details in GS:SFHS dataset. 
Genotyping data were generated using the Illumina Human OmniExpressExome -8- v1.0 array(1). Details of 
genotyping are described elsewhere(2). Quality control (QC) of genotyped SNPs used inclusion thresholds: missing 
SNPs per individual ≤2%, SNP genotype call rate ≥98%, minor allele frequency (MAF) >1% and Hardy-Weinberg 
equilibrium P value > 1 x 10-6. In total, 561,125 genotyped autosomal SNPs passed QC criteria and were used in the 
subsequent analyses. Haplotypes were identified using SHAPEIT for phasing with the option --duohmm which refines 
the phasing by pedigree information(3). Imputation was performed using the Sanger Imputation server 
(https://imputation.sanger.ac.uk/) (HRC). After removing imputed SNPs with info score <0.8 and MAF < 0.01, 
8,642,105 imputed SNPs remained.  
 
Diagnosis of MDD: A structured clinical interview was used for the diagnosis of lifetime DSM-IV mood disorders 
(SCID)(4,5). Participants screened positive for mental health problems by endorsing one or more screening questions: 
“Have you ever seen anybody for emotional or psychiatric problems? or “Was there ever a time when you, or 
someone else, thought you should see someone because of the way you were feeling or acting” (prevalence=21.7%). 
At the end of the screening questions, participants screening positive were invited to continue to an interview using the 
SCID modules for mood disorders(4). Participants were excluded from the study when: (1) they screened positive for 
mental health problems but refused to undergo the structured clinical interview (N=507) or (2) those who fulfilled 
criteria for Bipolar Disorder (N=76). This left 19,896 genotyped participants with 2,659 MDD cases and 17,237 
controls for the downstream analysis.  
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Text s2. Genotyping, quality control, imputation and phenotyping details in UK Biobank dataset. 
UK Biobank recruited around 500,000 people aged between 40-69 years in 2006-2010 across the United Kingdom 
(UK Biobank 2011a)(6).  
Genotyping and imputation: genotyping was performed for 152,729 UK Biobank participants using the Affymetrix 
UK Biobank Axiom array (N=102,750) and the Affymetrix UK BiLEVE Axiom array (N=49,979). Imputed data were 
generated by UK Biobank using a modified version of SHAPEIT for phasing and imputation was carried out using 
IMPUTE2, based on 1000 Genomes Phase 3 and UK10K haplotype panels(3,7). Additional QC was performed by 
removing SNPs with MAF < 0.01 and info score < 0.9. As the regional heritability analysis is highly computationally 
demanding, only those QC’ed imputed SNPs that could be mapped to the hapmap3 reference panel were used in 
downstream analyses(8). Additional filtering was performed for the genotyped subjects: 1) Non-white-British-
participants were removed to reduce possible population stratification, this left 120,091 participants. 2) Subjects who 
were in both GS:SFHS and UK Biobank datasets were removed. 3) One of each pair of close relatives (relatedness > 
0.05) of GS:SFSHS participants or the remained UK Biobank participants were removed from the UK Biobank 
sample. This left 116,981 genotyped participants.  
 
MDD phenotype: The probable MDD phenotype was created based on the putative MDD definition established in 
Smith et al (2013) using responses to a touchscreen questionnaire (UK Biobank 2011b)(9), from self-report 
information, and from inpatient records via linkage to hospital episode data. In detail, All controls were assessed to be 
absent of depressive symptoms(9) by satisfying the following criteria: (1) The answers are ‘No’ for the following 
touch screen questionnaire at recruitment: "Looking back over your life, have you ever had a time when you were 
feeling depressed or down for at least a whole week?",  "Have you ever seen a psychiatrist for nerves, anxiety, tension 
or depression?", "Have you ever had a time when you were uninterested in things or unable to enjoy the things you 
used to for at least a whole week?". (2) No primary diagnosis of ICD-10 Codes for mood disorders based on Hospital 
Episodes Data from UK bodies (English HES Data, Scottish Morbidity Register, Patient Episode Data). Cases 
satisfied the following criteria: (1) the answers of the following touchscreen questionnaire at recruitment are:  ‘Yes’ 
for "Have you ever seen a psychiatrist for nerves, anxiety, tension or depression?"; either ‘Yes’ for "Looking back 
over your life, have you ever had a time when you were feeling depressed or down for at least a whole week?" and 
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‘More than two weeks’ for "How many weeks was the longest period when you were feeling depressed or down?" or 
‘Yes’ for "Have you ever had a time when you were uninterested in things or unable to enjoy the things you used to 
for at least a whole week?" and ‘More than two weeks’ for "How many weeks was the longest period when you were 
uninterested in things or unable to enjoy the things you used to?". (2) Based on Hospital Episodes Data from UK 
bodies (English HES Data, Scottish Morbidity Register, Patient Episode Data, have a diagnosis of ICD-10 Codes for 
mood disorders. Additional sample filtering procedures were applied on the basis of self-report information and linked 
health records. Participants satisfying following criteria were excluded in the sample: (1)had been diagnosed to be 
bipolar disorder, multiple personality disorder, schizophrenia, autism, intellectual disability, Parkinson’s disease; or (2) 
self-reported bipolar disorder, schizophrenia, or Parkinson’s disease; or (3) bipolar disorder  indicated by a 
touchscreen questionnaire assessment(9); or (4) had a prescription for antipsychotic or mood stabilising medication. 
Participants were excluded as controls if they (1) had a diagnosis of an anxiety disorder, a mood disorder, or major 
depressive disorder; or (2)had ever been prescribed antidepressant or anxiolytic medication; (3) self-reported 
depression; or (4) if they did not provide sufficient data to respond to these questions, or if their responses were 
intermediate between the control and case definitions described above. In total, 1,198,327 SNPs for 24,015 subjects 
with putative MDD phenotype available (8,143 cases and 15,872 controls) remained in downstream analyses.   
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Text s3. Genotyping, quality control, imputation and phenotyping details in PGC2-MDD dataset. 
The Psychiatric Genomics Consortium provided lightly quality controlled (Missing-rate < 2%) individual genotypes 
(best guess) of imputed SNPs for participants from 22 cohorts in PGC2-MDD (Table s1).Subjects who overlapped 
with GS:SFHS and UK Biobank dataset (108 subjects) were removed. The remained data included 32,554 subjects of 
European ancestry (13,261 cases and 19,293 controls). We carried out additional QC for the imputed SNPs using the 
following inclusion thresholds: info score≥ 0.8, and MAF≥0.01. For each cohort, imputed SNPs that passed QC and 
could be mapped to the hapmap3 reference panel were used in downstream analyses (Table s1).  All cases met DSM-
IV criteria for life MDD, the majority of them were ascertained clinically. Most control samples were screened and 
participants with lifetime MDD were removed (Table s1).  Consistent with earlier work(10,11), we grouped the 22 
cohorts into 7 groups based on the country of ancestor information for regional heritability analysis (Table s1).
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Text s4. Genome-wide haplotype-block-based Regional Heritability Mapping (HRHM) 
To perform HRHM, estimated genome-wide recombination rates expressed as cM/Mb were downloaded from 
HapMap(phase II)(ftp://ftp.ncbi.nlm.nih.gov/hapmap). For each chromosome, we started from the first base position 
and expanded the region until it reached a recombination hot-spot where the estimated recombination rate was greater 
than 10 cM/Mb. This hot-spot marked the end of the region and the start of the next. This process continued until the 
end of chromosome was reached. Each region was considered to be a haplotype block. The genotyped SNPs were 
mapped to 49,637 haplotype-blocks across the genome and the regional heritability was estimated and tested for each 
of the haplotype-blocks.  To test the regional heritability, it is necessary to appropriately account for the polygenic 
component and the pedigree structure in the analysis model. A standard model incorporates two genomic relationship 
matrices (GRM); a regional genomic relationship matrix (rGRM) estimated from SNPs in the haplotype block and a 
complement genomic relationship matrix (cGRM) estimated from all SNPs that are not included in in the haplotype 
block. These GRMs were jointly fitted in LMM: 
Y = Xb + gR + gC + e 
Var(Yrandom_effect) = AR   + AC    + I    
  
  =    /   random_effect 
Where Y is a vector of MDD binary phenotypes, b is a vector of covariates fitted as fixed effects (i.e., age, age2, sex, 
20 principal components derived from the GRM created using all of the genotyped SNPs (fGRM)). gR and gC are the 
random genetic effects from the regional SNPs (in this study, the SNPs that were mapped to the haplotype-block) and 
the complement set of SNPs, respectively. AR and AC are the GRMs created from the regional SNPs and the 
complement set of SNPs, respectively. The variance explained by the rGRM variance component (regional heritability 
  
 ) is estimated using restricted estimated maximum likelihood (REML). The estimate is transformed from the 
observed scale to the liability scale assuming MDD prevalence of 0.13(5). A Log likelihood ratio test (LRT) is applied 
to test the significance of random effect represented in rGRM by comparing a model with both cGRM and an rGRM 
fitted against a model including the cGRM but without an rGRM fitted. 
 
Yanni Zeng            
 
 7 
The two-GRM model, while providing an unbiased estimate of regional heritability, was highly computationally 
demanding. To improve the calculation efficiency, a pre-adjustment strategy was applied in the genome-wide HRHM. 
In detail, we created genomic relationship matrix using all of the genotyped SNPs (fGRM)(12) and pre-adjusted the 
random effect represented in the fGRM for the MDD phenotype using the ‘polygenic’ function in GenABEL(13). 
Residuals (pgresidualY option) were extracted from the model and used as the phenotype in the HRHM(13). The 
HRHM was performed by REACTA(14) using the following formula:   
 Ygresidual = Xb + gR + e 
Var(Ygresidual_random_effect) = AR   + I    
  
  =    /    gresidual_random_effect 
Where Ygresidual is a vector of the residuals with fGRM being pre-adjusted, other parameters are the same as in the two-
GRM-model. Multiple-testing-correction was performed for LRT statistics using the Bonferrroni method and the 
genome-wide significance threshold for HRHM was determined by the number of tests conducted (Nblocks=49,637)(15). 
The genome-wide significance threshold for P values from LRT is 1.01x10-6. For haplotype-blocks that exceeded the 
genome-wide significant threshold, we re-tested the block using the two-GRM model to provide an accurate 
estimation of regional heritability in the target block. All the analyses were performed in REACTA(14,16).
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Text s5 Single-haplotype-based association test 
Full dataset containing both relatives and non-relatives: association tests were performed using GCTA-MLMA(12). 
For each participant, individual haplotypes were coded as 0, 1 or 2. In the linear mixed model, the effect from each 
haplotype on MDD phenotype was tested one at a time as a fixed effect, other covariates included age, age2, sex and 
20PCs. As in the single-SNP-based association test, two GRMs were fitted simultaneously as random effects in the 
model. Bonferroni multiple-testing correction was performed for the P values of each haplotype. 
 
Unrelated dataset (Ncase=997, Ncontrol=6367):  the dataset was generated by removing one of each pair of individuals 
with estimated relatedness larger than 0.025 by the function ‘--grm-cutoff 0.025’ in GCTA(12). Association tests on 
the unrelated dataset were performed using GCTA-MLMA. Since the unrelated dataset contained no pair of 
individuals with a relatedness larger then 0.025, only the cGRM was fitted in the model.   
 
Case-parent trios (Ncase-parents trios=315): family-triad based logistic Bayesian Lasso (famLBL) is a method designed for 
testing the effects of haplotypes on diseases using SNP data using the triad family where the child is affected by the 
disease and both the child and parents have genotype and disease diagnosis information available(17). This method 
shrinks the coefficients of unassociated haplotypes and weighted toward rare haplotypes while retaining sufficient 
power for detecting common haplotype, allowing for more precise estimation of associated haplotypes(17). The 
confidence interval (CI) of OR and the Bayes Factor(BF) were given in the results  and the BF threshold of 2 was 
applied (type I error rate ≤ 5%)(17). 
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Text s6. Functional annotation tools and analyses for MDD-associated SNPs.  
(1)Regulomedb is a database providing annotations of known or predicted regulatory functions of non-coding variants. 
A score was provided for each SNP based on evidence from high-throughput experimental data as well as 
computational predictions and manual annotations to represent whether the SNP is likely to alter the binding of 
transcription factors(18).  
(2) Genome Wide Annotation of VAriants (GWAVA) is a tool providing prediction of the functional influence of non-
coding variants based on annotations of non-coding elements along with genome-wide properties, such as 
evolutionary conservation and GC-content(19). 
(3) Genomic Evolutionary Rate Profiling (GERP) is a method providing estimates of evolutionary constraint with 
single variant resolution using maximum likelihood evolutionary rate estimation. A score threshold of 2 provides high 
sensitivity while still strongly enriching for truly constrained sites(20). 
(4) Allelic effect on gene-expression (eQTL analysis). 
In GTEX (http://www.gtexportal.org/home/datasets), tissue-specific SNP-cis-gene association test results were 
available from 11 brain tissues (a cis window was defined as +/- 1MB around the transcript start site (TSS).). The 
information available includes test statistics (a two tailed t-test) of the effect of the alternative allele relative to the 
reference allele on the expression of the gene for each SNP-gene pair in each tissue. We downloaded the 11 files and 
only extracted the records for the 38 SNPs. In BRAINEAC, tissue-specific SNP-cis-gene association test results were 
available from 10 brain tissues. P values from the tissue-specific cis-eQTL analyses were downloaded from 
http://caprica.genetics.kcl.ac.uk/BRAINEAC/. In results extracted from both GTEX and BRAINEAC, FDR multiple 
testing correction was applied to each tissue separately using the R package ‘qvalue’(21)(Ncorrection=Ncis-genes*Nsnps). 
(5) Allelic effect on DNA methylation in CpG loci (meQTL analysis). 
Jaffe et.al.,(2016) identified meQTLs in frontal cortex using SNP-cis-CpG DNA methylation analysis on 258 adult 
control samples (age > 13)(22). Additionally, they also identified CpG loci that have differential DNA methylation 
level between fetal and postnatal life, which suggests a role of those loci in the early development stage in frontal 
cortex. We have extracted the records of the 38 SNPs from the downloaded summary statistics file of the SNP-cis-
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CpG DNA methylation analysis, this included FDR values for each pair of associations and the estimate of the SNP 
effect (Beta). For the CpG loci that were significantly regulated by the 38 SNPs, we further checked the summary 
statistics file of the CpG loci differentially DNA methylated between fetal and postnatal life to see whether the 
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OR logOR se(logOR) P Adjusted P 
rs4812766 20 42559149 A G 0.096 -0.026 0.006 0.780 -0.248 0.045 1.72E-05 9.10E-04 * 
rs11905261 20 42566120 C A 0.096 -0.025 0.006 0.782 -0.246 0.045 1.99E-05 1.05E-03 * 
rs78295570 20 42567815 T C 0.097 -0.025 0.006 0.783 -0.245 0.045 2.00E-05 1.06E-03 * 
rs6093898 20 42566577 G A 0.097 -0.025 0.006 0.783 -0.245 0.045 2.03E-05 1.08E-03 * 
rs6103524 20 42568152 G A 0.097 -0.025 0.006 0.783 -0.245 0.045 2.03E-05 1.08E-03 * 
rs77591323 20 42567817 C T 0.097 -0.025 0.006 0.783 -0.245 0.045 2.10E-05 1.11E-03 * 
rs6031245 20 42559531 T C 0.096 -0.025 0.006 0.783 -0.244 0.045 2.30E-05 1.22E-03 * 
rs75074505 20 42567941 G C 0.097 -0.025 0.006 0.784 -0.243 0.045 2.31E-05 1.22E-03 * 
rs1888982 20 42566009 A G 0.097 -0.025 0.006 0.784 -0.243 0.045 2.31E-05 1.23E-03 * 
rs916474 20 42563571 A G 0.096 -0.025 0.006 0.784 -0.244 0.045 2.36E-05 1.25E-03 * 
rs79225010 20 42557504 A G 0.096 -0.025 0.006 0.784 -0.244 0.045 2.38E-05 1.26E-03 * 
rs868981 20 42562557 A G 0.096 -0.025 0.006 0.784 -0.243 0.045 2.46E-05 1.30E-03 * 
rs11086910 20 42579473 A G 0.095 -0.025 0.006 0.783 -0.244 0.045 2.49E-05 1.32E-03 * 
rs4812767 20 42568829 T C 0.096 -0.025 0.006 0.785 -0.242 0.045 2.57E-05 1.36E-03 * 
rs944703 20 42564176 C A 0.096 -0.025 0.006 0.785 -0.242 0.045 2.62E-05 1.39E-03 * 
rs79645278 20 42568164 T C 0.096 -0.025 0.006 0.785 -0.242 0.045 2.67E-05 1.41E-03 * 
rs2002343 20 42570003 A G 0.096 -0.025 0.006 0.785 -0.242 0.045 2.67E-05 1.41E-03 * 
rs4383390 20 42572303 C T 0.096 -0.025 0.006 0.785 -0.242 0.045 2.67E-05 1.41E-03 * 
rs56852079 20 42562168 A G 0.096 -0.025 0.006 0.786 -0.241 0.045 2.85E-05 1.51E-03 * 
rs57150899 20 42562169 T C 0.096 -0.025 0.006 0.786 -0.241 0.045 2.86E-05 1.52E-03 * 
rs4812770 20 42575630 G C 0.097 -0.025 0.006 0.789 -0.237 0.045 3.62E-05 1.92E-03 * 
rs11907990 20 42556041 T C 0.096 -0.024 0.006 0.790 -0.235 0.045 4.24E-05 2.24E-03 * 
rs11906108 20 42556057 T A 0.096 -0.024 0.006 0.790 -0.235 0.045 4.24E-05 2.24E-03 * 
rs76623859 20 42555756 A C 0.096 -0.024 0.006 0.791 -0.235 0.045 4.47E-05 2.37E-03 * 
rs910909 20 42575799 G A 0.096 -0.024 0.006 0.792 -0.233 0.045 4.84E-05 2.57E-03 * 
rs910907 20 42576998 T G 0.095 -0.024 0.006 0.793 -0.231 0.045 5.85E-05 3.10E-03 * 
rs4812771 20 42575733 T C 0.095 -0.024 0.006 0.793 -0.231 0.045 5.87E-05 3.11E-03 * 
rs910908 20 42575841 A G 0.095 -0.024 0.006 0.793 -0.231 0.045 5.87E-05 3.11E-03 * 
rs6093895 20 42557501 A G 0.118 -0.021 0.005 0.819 -0.200 0.042 1.08E-04 5.71E-03 * 
rs6130482 20 42557999 C T 0.118 -0.021 0.005 0.819 -0.200 0.042 1.09E-04 5.77E-03 * 
rs743152 20 42569911 T G 0.106 -0.022 0.006 0.811 -0.209 0.044 1.20E-04 6.34E-03 * 
rs6017223 20 42571020 G C 0.106 -0.022 0.006 0.814 -0.206 0.044 1.60E-04 8.47E-03 * 
rs6017220 20 42564336 C T 0.107 -0.021 0.006 0.816 -0.204 0.044 1.72E-04 9.12E-03 * 
rs6103521 20 42566398 G T 0.106 -0.021 0.006 0.816 -0.203 0.044 1.75E-04 9.28E-03 * 
rs6103517 20 42558608 A G 0.118 -0.020 0.005 0.825 -0.192 0.042 1.92E-04 1.02E-02 * 
rs6017218 20 42555737 G T 0.126 -0.019 0.005 0.833 -0.183 0.041 2.44E-04 1.29E-02 * 
rs6031242 20 42556096 G A 0.113 -0.019 0.006 0.832 -0.184 0.043 4.36E-04 2.31E-02 * 
rs6103516 20 42556151 G A 0.113 -0.019 0.006 0.834 -0.181 0.043 5.39E-04 2.86E-02 * 
rs138949844 20 42570224 T C 0.026 0.027 0.011 1.245 0.219 0.120 1.51E-02 1.00E+00 
rs4812773 20 42579148 T C 0.261 0.008 0.004 1.074 0.071 0.037 3.79E-02 1.00E+00 
rs4812772 20 42579051 T C 0.261 0.008 0.004 1.072 0.070 0.037 4.19E-02 1.00E+00 
rs6031247 20 42563647 A G 0.147 -0.010 0.005 0.915 -0.089 0.041 4.89E-02 1.00E+00 
rs141048930 20 42567378 G T 0.015 -0.027 0.014 0.767 -0.266 0.106 5.59E-02 1.00E+00 
rs4812769 20 42574442 T C 0.251 0.007 0.004 1.065 0.063 0.038 6.94E-02 1.00E+00 
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rs73118242 20 42568478 C T 0.012 -0.017 0.016 0.853 -0.159 0.128 2.94E-01 1.00E+00 
rs11700304 20 42574362 C T 0.374 -0.004 0.004 0.968 -0.032 0.031 3.17E-01 1.00E+00 
rs4812774 20 42579188 C T 0.373 -0.004 0.004 0.969 -0.031 0.031 3.33E-01 1.00E+00 
rs76571595 20 42572032 G T 0.012 -0.014 0.016 0.879 -0.129 0.129 3.82E-01 1.00E+00 
rs6031252 20 42573822 A C 0.010 0.015 0.018 1.137 0.128 0.174 3.89E-01 1.00E+00 
rs761919 20 42577362 C T 0.372 -0.003 0.004 0.973 -0.028 0.031 3.93E-01 1.00E+00 
rs73118230 20 42556503 C T 0.012 -0.011 0.016 0.908 -0.097 0.131 5.06E-01 1.00E+00 
rs79663350 20 42573034 A G 0.028 0.001 0.011 1.009 0.009 0.095 9.20E-01 1.00E+00 
rs8117150 20 42569690 A G 0.015 0.001 0.015 1.007 0.007 0.130 9.59E-01 1.00E+00 
 
Table s5 Results of Single-SNP-based association test on 53 imputed common SNPs in the hit block in GS:SFHS. 
Adjusted P: Bonferroni method adjusted P value. *: significant results. 
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rs id Pos Chr A1 RegulomeDB GWAVA-TSS GERP 
rs6017218 42555737 20 G 4 0.180 3.340 
rs76623859 42555756 20 A 2b 0.180 -0.046 
rs11907990 42556041 20 T 4 0.290 -2.900 
rs11906108 42556057 20 T 4 0.240 -3.340 
rs6031242 42556096 20 G 5 0.350 -5.020 
rs6103516 42556151 20 G 5 0.120 -0.218 
rs6093895 42557501 20 A 5 0.150 -1.560 
rs79225010 42557504 20 A 5 0.130 0.780 
rs6130482 42557999 20 C 5 0.090 -3.660 
rs6103517 42558608 20 A 7 0.090 -0.633 
rs4812766 42559149 20 A 5 0.180 1.860 
rs6031245 42559531 20 T 7 0.360 -3.070 
rs56852079 42562168 20 A 5 0.330 -4.140 
rs57150899 42562169 20 T 5 0.190 -1.260 
rs868981 42562557 20 A 5 0.330 2.250 
rs916474 42563571 20 A 5 0.310 0.489 
rs944703 42564176 20 C 5 0.180 -4.940 
rs6017220 42564336 20 C 6 0.160 0.235 
rs1888982 42566009 20 A 5 0.280 -2.420 
rs11905261 42566120 20 C 5 0.300 0.964 
rs6103521 42566398 20 G 4 0.240 -3.570 
rs6093898 42566577 20 G 4 0.200 0.442 
rs78295570 42567815 20 T 4 0.470 -5.270 
rs77591323 42567817 20 C 4 0.530 -5.770 
rs75074505 42567941 20 G 4 0.400 -1.570 
rs6103524 42568152 20 G 4 0.510 2.290 
rs79645278 42568164 20 T 2b 0.500 2.310 
rs4812767 42568829 20 T 4 0.350 -0.751 
rs743152 42569911 20 T 6 0.380 -1.980 
rs2002343 42570003 20 A 7 0.330 -0.470 
rs6017223 42571020 20 G 3a 0.510 -4.170 
rs4383390 42572303 20 C 6 0.520 -2.190 
rs4812770 42575630 20 G 5 0.120 1.370 
rs4812771 42575733 20 T 7 0.180 2.090 
rs910909 42575799 20 G 7 0.130 1.310 
rs910908 42575841 20 A 6 0.120 -2.430 
rs910907 42576998 20 T 5 0.200 -1.160 
rs11086910 42579473 20 A 4 0.300 -1.820 
 
Table s6 The functional prediction of 38 significant SNPs using regulomeDB score, GWAVA-Tss score and GERP 
score.




Table s7 Significant results (Q value ≤ 0.05) from SNP-cis-gene-eQTL analysis using GTEX. The analysis were 
performed on 11 brain tissues in GTEX and significant results were obtained from the tissue ‘Nucleus accumbens 
basal ganglia’. A1 is the tested allele, the same allele tested in single-SNP-based association test. Q value: Adjusted P 
values(FDR)
rs id Pos Chr A1 Genename Gene_pos eQTL_beta eQTL_P eQTL_Qvalue 
rs78295570 42567815 20 T RP1-
269M15.3 
20_41818862-41830011 0.373132 2.35E-04 3.17E-02 
rs77591323 42567817 20 C RP1-
269M15.3 
20_41818862-41830011 0.373132 2.35E-04 3.17E-02 
rs75074505 42567941 20 G RP1-
269M15.3 
20_41818862-41830011 unsigned_0.373132 2.35E-04 3.17E-02 
rs6103524 42568152 20 G RP1-
269M15.3 
20_41818862-41830011 0.373132 2.35E-04 3.17E-02 
rs1888982 42566009 20 A RP1-
269M15.3 
20_41818862-41830011 0.373229 2.36E-04 3.17E-02 
rs56852079 42562168 20 A RP1-
269M15.3 
20_41818862-41830011 0.357319 2.52E-04 3.17E-02 
rs910909 42575799 20 G RP1-
269M15.3 
20_41818862-41830011 0.352567 2.94E-04 3.17E-02 
rs11086910 42579473 20 A RP1-
269M15.3 
20_41818862-41830011 0.381632 4.45E-04 4.10E-02 
rs6093898 42566577 20 G RP1-
269M15.3 
20_41818862-41830011 0.357227 4.89E-04 4.10E-02 
rs743152 42569911 20 T RP1-
269M15.3 
20_41818862-41830011 0.3497 8.18E-04 4.25E-02 
rs6103521 42566398 20 G RP1-
269M15.3 
20_41818862-41830011 0.336035 8.66E-04 4.25E-02 
rs6017220 42564336 20 C RP1-
269M15.3 
20_41818862-41830011 0.335674 8.85E-04 4.25E-02 
rs11905261 42566120 20 C RP1-
269M15.3 
20_41818862-41830011 0.338646 9.06E-04 4.25E-02 
rs11906108 42556057 20 T RP1-
269M15.3 
20_41818862-41830011 unsigned_0.35263 1.09E-03 4.25E-02 
rs868981 42562557 20 A RP1-
269M15.3 
20_41818862-41830011 0.31452 1.18E-03 4.25E-02 
rs57150899 42562169 20 T RP1-
269M15.3 
20_41818862-41830011 0.361794 1.41E-03 4.25E-02 
rs11907990 42556041 20 T RP1-
269M15.3 
20_41818862-41830011 0.347766 1.46E-03 4.25E-02 
rs4383390 42572303 20 C RP1-
269M15.3 
20_41818862-41830011 0.345133 1.59E-03 4.25E-02 
rs6031245 42559531 20 T RP1-
269M15.3 
20_41818862-41830011 0.345064 1.59E-03 4.25E-02 
rs79645278 42568164 20 T RP1-
269M15.3 
20_41818862-41830011 0.345064 1.59E-03 4.25E-02 
rs4812767 42568829 20 T RP1-
269M15.3 
20_41818862-41830011 0.345064 1.59E-03 4.25E-02 
rs2002343 42570003 20 A RP1-
269M15.3 
20_41818862-41830011 0.345064 1.59E-03 4.25E-02 
rs4812771 42575733 20 T RP1-
269M15.3 
20_41818862-41830011 0.345064 1.59E-03 4.25E-02 
rs910908 42575841 20 A RP1-
269M15.3 
20_41818862-41830011 0.345064 1.59E-03 4.25E-02 
rs910907 42576998 20 T RP1-
269M15.3 
20_41818862-41830011 0.345064 1.59E-03 4.25E-02 
rs4812766 42559149 20 A RP1-
269M15.3 
20_41818862-41830011 0.344928 1.60E-03 4.25E-02 
rs79225010 42557504 20 A RP1-
269M15.3 
20_41818862-41830011 0.344801 1.60E-03 4.25E-02 
rs944703 42564176 20 C RP1-
269M15.3 
20_41818862-41830011 0.344844 1.62E-03 4.25E-02 
rs916474 42563571 20 A RP1-
269M15.3 
20_41818862-41830011 0.344701 1.63E-03 4.25E-02 
rs76623859 42555756 20 A RP1-
269M15.3 
20_41818862-41830011 0.344566 1.71E-03 4.29E-02 
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Gene Symbol rs id Chr Pos exprID Gene_start Gene_end P Q 
TOX2,LOC100128170 rs4383390 20 42572303 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs2002343 20 42570003 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs868981 20 42562557 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs916474 20 42563571 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs944703 20 42564176 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs79225010 20 42557504 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs6031245 20 42559531 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs6093898 20 42566577 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs78295570 20 42567815 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs77591323 20 42567817 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs75074505 20 42567941 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs6103524 20 42568152 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs79645278 20 42568164 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs4812767 20 42568829 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs4812766 20 42559149 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs1888982 20 42566009 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs11905261 20 42566120 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs910909 20 42575799 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs910908 20 42575841 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs4812771 20 42575733 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs76623859 20 42555756 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs11907990 20 42556041 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs11906108 20 42556057 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs910907 20 42576998 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs743152 20 42569911 t3886294 42543004 42710556 1.60E-05 3.06E-04 
TOX2,LOC100128170 rs6017223 20 42571020 t3886294 42543004 42710556 1.60E-05 3.06E-04 
TOX2,LOC100128170 rs6103521 20 42566398 t3886294 42543004 42710556 1.60E-05 3.06E-04 
TOX2,LOC100128170 rs6017220 20 42564336 t3886294 42543004 42710556 1.60E-05 3.06E-04 
TOX2,LOC100128170 rs11086910 20 42579473 t3886294 42543004 42710556 1.80E-05 3.06E-04 
TOX2,LOC100128170 rs6031242 20 42556096 t3886294 42543004 42710556 5.00E-06 3.06E-04 
TOX2,LOC100128170 rs6103516 20 42556151 t3886294 42543004 42710556 5.00E-06 3.06E-04 
TOX2,LOC100128170 rs4812770 20 42575630 t3886294 42543004 42710556 2.00E-05 3.29E-04 
TOX2,LOC100128170 rs6017218 20 42555737 t3886294 42543004 42710556 2.10E-05 3.35E-04 
TOX2,LOC100128170 rs6130482 20 42557999 t3886294 42543004 42710556 6.70E-05 1.04E-03 
TOX2,LOC100128170 rs6093895 20 42557501 t3886294 42543004 42710556 6.90E-05 1.04E-03 
TOX2,LOC100128170 rs57150899 20 42562169 t3886294 42543004 42710556 0.00026 3.70E-03 
TOX2,LOC100128170 rs56852079 20 42562168 t3886294 42543004 42710556 0.00026 3.70E-03 
TOX2,LOC100128170 rs6103517 20 42558608 t3886294 42543004 42710556 0.00078 1.08E-02 
 
Table s8 Significant results (Q value ≤ 0.05) from SNP-cis-gene-eQTL analysis on Frontal cortex using BRAINEAC. 
The analysis was performed on 10 brain tissues in BRAINEAC and significant results were obtained from two tissues: 
Frontal cortex and Cerebellar cortex. A1 is the tested allele, the same allele tested in single-SNP-based association test. 
P: p values from SNP-cis-gene-eQTL analysis. Q:  Adjusted P values(FDR)
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Gene Symbol Pos Chr rs id exprID chr Gene_start Gene_start P Q 
C20orf62 42572303 20 rs4383390 t3906923 chr20 43080624 43093984 8.70E-04 2.34E-02 
C20orf62 42566009 20 rs1888982 t3906923 chr20 43080624 43093984 8.70E-04 2.34E-02 
C20orf62 42566120 20 rs11905261 t3906923 chr20 43080624 43093984 8.70E-04 2.34E-02 
C20orf62 42570003 20 rs2002343 t3906923 chr20 43080624 43093984 8.80E-04 2.34E-02 
C20orf62 42563571 20 rs916474 t3906923 chr20 43080624 43093984 8.80E-04 2.34E-02 
C20orf62 42564176 20 rs944703 t3906923 chr20 43080624 43093984 8.80E-04 2.34E-02 
C20orf62 42559531 20 rs6031245 t3906923 chr20 43080624 43093984 8.80E-04 2.34E-02 
C20orf62 42566577 20 rs6093898 t3906923 chr20 43080624 43093984 8.80E-04 2.34E-02 
C20orf62 42567815 20 rs78295570 t3906923 chr20 43080624 43093984 8.80E-04 2.34E-02 
C20orf62 42567817 20 rs77591323 t3906923 chr20 43080624 43093984 8.80E-04 2.34E-02 
C20orf62 42567941 20 rs75074505 t3906923 chr20 43080624 43093984 8.80E-04 2.34E-02 
C20orf62 42568152 20 rs6103524 t3906923 chr20 43080624 43093984 8.80E-04 2.34E-02 
C20orf62 42568164 20 rs79645278 t3906923 chr20 43080624 43093984 8.80E-04 2.34E-02 
C20orf62 42568829 20 rs4812767 t3906923 chr20 43080624 43093984 8.80E-04 2.34E-02 
C20orf62 42562557 20 rs868981 t3906923 chr20 43080624 43093984 8.80E-04 2.34E-02 
C20orf62 42559149 20 rs4812766 t3906923 chr20 43080624 43093984 8.80E-04 2.34E-02 
C20orf62 42575630 20 rs4812770 t3906923 chr20 43080624 43093984 8.50E-04 2.34E-02 
C20orf62 42575841 20 rs910908 t3906923 chr20 43080624 43093984 8.70E-04 2.34E-02 
C20orf62 42575733 20 rs4812771 t3906923 chr20 43080624 43093984 8.70E-04 2.34E-02 
C20orf62 42575799 20 rs910909 t3906923 chr20 43080624 43093984 8.70E-04 2.34E-02 
C20orf62 42555756 20 rs76623859 t3906923 chr20 43080624 43093984 8.80E-04 2.34E-02 
C20orf62 42556041 20 rs11907990 t3906923 chr20 43080624 43093984 8.80E-04 2.34E-02 
C20orf62 42556057 20 rs11906108 t3906923 chr20 43080624 43093984 8.80E-04 2.34E-02 
C20orf62 42564336 20 rs6017220 t3906923 chr20 43080624 43093984 8.90E-04 2.34E-02 
C20orf62 42566398 20 rs6103521 t3906923 chr20 43080624 43093984 8.90E-04 2.34E-02 
C20orf62 42569911 20 rs743152 t3906923 chr20 43080624 43093984 9.00E-04 2.34E-02 
C20orf62 42571020 20 rs6017223 t3906923 chr20 43080624 43093984 9.00E-04 2.34E-02 
C20orf62 42576998 20 rs910907 t3906923 chr20 43080624 43093984 8.70E-04 2.34E-02 
C20orf62 42557504 20 rs79225010 t3906923 chr20 43080624 43093984 9.10E-04 2.34E-02 
C20orf62 42579473 20 rs11086910 t3906923 chr20 43080624 43093984 8.70E-04 2.34E-02 
C20orf62 42562169 20 rs57150899 t3906923 chr20 43080624 43093984 2.80E-04 2.34E-02 
C20orf62 42562168 20 rs56852079 t3906923 chr20 43080624 43093984 2.80E-04 2.34E-02 
C20orf62 42556096 20 rs6031242 t3906923 chr20 43080624 43093984 1.10E-03 2.66E-02 
C20orf62 42556151 20 rs6103516 t3906923 chr20 43080624 43093984 1.10E-03 2.66E-02 
C20orf62 42558608 20 rs6103517 t3906923 chr20 43080624 43093984 2.70E-03 6.35E-02 
 
Table s9 Significant results (Q value ≤ 0.05) from SNP-cis-gene-eQTL analysis on Cerebellar cortex using 
BRAINEAC. The analysis was performed on 10 brain tissues in BRAINEAC and significant results were obtained 
from two tissues: Frontal cortex and Cerebellar cortex. A1 is the tested allele, the same allele tested in single-SNP-
based association test. P: p values from SNP-cis-gene-eQTL analysis. Q:  Adjusted P values(FDR).
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Replication Sample Group Plrt     se(   )     se(   ) 
PGC2-MDD Combined 22 0.500 0.000 0.000 0.139 0.012 
PGC2-MDD AUS the matrix V becomes negative-definite 
PGC2-MDD GER 0.415 0.000 0.001 0.357 0.064 
PGC2-MDD MIXED 0.500 0.000 0.002 0.157 0.159 
PGC2-MDD NET 0.500 0.000 0.001 0.351 0.081 
PGC2-MDD SWE 0.068 0.003 0.004 0.341 0.115 
PGC2-MDD UK-Ireland 0.049* 0.001 0.001 0.227 0.051 
PGC2-MDD USA 0.500 0.000 0.001 0.252 0.079 
UK Biobank UK Biobank 0.151 0.000 0.000 0.130 0.019 
 
Table s11 Regional heritability estimates of the hit block in seven groups and the combined (22 cohorts) in PGC2-
MDD and UK Biobank.   
 
:  regional heritability. Plrt:  P value of LRT for    . 
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rs id Pos Chr Cohort A1 OR logOR se(logOR) P 
rs6017218 42555737 20 boma G 1.006 0.006 0.120 0.960 
rs6017218 42555737 20 cof3 G 0.746 -0.293 0.279 0.294 
rs6017218 42555737 20 gep3 G 0.916 -0.087 0.180 0.626 
rs6017218 42555737 20 grdg G 0.966 -0.035 0.139 0.801 
rs6017218 42555737 20 grnd G 0.939 -0.063 0.131 0.632 
rs6017218 42555737 20 gsk2 G 0.924 -0.079 0.103 0.446 
rs6017218 42555737 20 i2b3 G 1.160 0.148 0.100 0.139 
rs6017218 42555737 20 mmi2 G 1.150 0.140 0.130 0.284 
rs6017218 42555737 20 mmo4 G 1.089 0.085 0.213 0.690 
rs6017218 42555737 20 qi3c G 0.968 -0.032 0.114 0.776 
rs6017218 42555737 20 qi6c G 1.019 0.019 0.131 0.886 
rs6017218 42555737 20 qio2 G 1.168 0.155 0.136 0.252 
rs6017218 42555737 20 rad3 G 0.824 -0.193 0.076 0.011 * 
rs6017218 42555737 20 rage G 1.020 0.020 0.208 0.924 
rs6017218 42555737 20 rai2 G 0.903 -0.102 0.265 0.699 
rs6017218 42555737 20 rau2 G 1.455 0.375 0.188 0.046 * 
rs6017218 42555737 20 rde4 G 1.382 0.324 0.212 0.127 
rs6017218 42555737 20 rot4 G 0.770 -0.262 0.164 0.111 
rs6017218 42555737 20 twg2 G 1.092 0.088 0.076 0.248 
rs6031242 42556096 20 boma G 1.033 0.032 0.122 0.791 
rs6031242 42556096 20 cof3 G 0.638 -0.449 0.296 0.129 
rs6031242 42556096 20 gep3 G 0.963 -0.038 0.185 0.838 
rs6031242 42556096 20 grdg G 0.918 -0.086 0.148 0.564 
rs6031242 42556096 20 grnd G 0.938 -0.064 0.137 0.643 
rs6031242 42556096 20 gsk2 G 0.921 -0.082 0.105 0.435 
rs6031242 42556096 20 i2b3 G 1.041 0.040 0.107 0.708 
rs6031242 42556096 20 mmi2 G 1.182 0.167 0.144 0.246 
rs6031242 42556096 20 mmo4 G 1.239 0.214 0.221 0.333 
rs6031242 42556096 20 qi3c G 0.950 -0.052 0.123 0.674 
rs6031242 42556096 20 qi6c G 1.090 0.086 0.141 0.540 
rs6031242 42556096 20 qio2 G 1.154 0.143 0.143 0.317  
rs6031242 42556096 20 rad3 G 0.841 -0.174 0.080 0.031 * 
rs6031242 42556096 20 rage G 1.057 0.055 0.214 0.796 
rs6031242 42556096 20 rai2 G 0.854 -0.158 0.278 0.569 
rs6031242 42556096 20 rau2 G 1.344 0.296 0.198 0.135 
rs6031242 42556096 20 rde4 G 1.287 0.252 0.216 0.244 
rs6031242 42556096 20 rot4 G 0.652 -0.428 0.179 0.017 * 
rs6031242 42556096 20 twg2 G 1.075 0.072 0.079 0.362 
rs6031245 42559531 20 boma T 0.999 -0.001 0.137 0.997 
rs6031245 42559531 20 cof3 T 0.626 -0.468 0.347 0.177 
rs6031245 42559531 20 col3 T 0.901 -0.104 0.140 0.458 
rs6031245 42559531 20 edi2 T 0.895 -0.111 0.204 0.586 
rs6031245 42559531 20 gep3 T 0.892 -0.115 0.215 0.592 
rs6031245 42559531 20 grdg T 0.964 -0.037 0.163 0.821 
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rs6031245 42559531 20 grnd T 0.925 -0.078 0.154 0.615 
rs6031245 42559531 20 gsk2 T 0.930 -0.073 0.122 0.549 
rs6031245 42559531 20 i2b3 T 1.080 0.077 0.122 0.529 
rs6031245 42559531 20 mmi2 T 0.978 -0.023 0.157 0.885 
rs6031245 42559531 20 mmo4 T 1.259 0.230 0.249 0.355 
rs6031245 42559531 20 nes1 T 1.050 0.049 0.092 0.597 
rs6031245 42559531 20 qi3c T 1.005 0.005 0.131 0.970 
rs6031245 42559531 20 qi6c T 1.161 0.149 0.155 0.336 
rs6031245 42559531 20 qio2 T 1.086 0.083 0.166 0.619 
rs6031245 42559531 20 rad3 T 0.837 -0.178 0.091 0.052 
rs6031245 42559531 20 rage T 1.355 0.304 0.263 0.248 
rs6031245 42559531 20 rai2 T 0.715 -0.336 0.306 0.272 
rs6031245 42559531 20 rau2 T 1.323 0.280 0.210 0.183 
rs6031245 42559531 20 rde4 T 1.100 0.095 0.239 0.690 
rs6031245 42559531 20 rot4 T 0.551 -0.596 0.225 0.008 * 
rs6031245 42559531 20 twg2 T 1.133 0.125 0.089 0.162 
rs6093898 42566577 20 boma G 0.968 -0.032 0.137 0.814 
rs6093898 42566577 20 cof3 G 0.672 -0.397 0.343 0.247 
rs6093898 42566577 20 col3 G 0.898 -0.107 0.140 0.445 
rs6093898 42566577 20 edi2 G 0.933 -0.069 0.204 0.735 
rs6093898 42566577 20 gep3 G 0.884 -0.124 0.215 0.564 
rs6093898 42566577 20 grdg G 0.947 -0.055 0.163 0.737 
rs6093898 42566577 20 grnd G 0.944 -0.058 0.154 0.710 
rs6093898 42566577 20 gsk2 G 0.923 -0.080 0.122 0.512 
rs6093898 42566577 20 i2b3 G 1.094 0.090 0.121 0.460 
rs6093898 42566577 20 mmi2 G 0.985 -0.015 0.157 0.922 
rs6093898 42566577 20 mmo4 G 1.137 0.128 0.247 0.603 
rs6093898 42566577 20 nes1 G 1.041 0.040 0.090 0.657 
rs6093898 42566577 20 qi3c G 1.027 0.027 0.135 0.844 
rs6093898 42566577 20 qi6c G 1.161 0.149 0.155 0.335 
rs6093898 42566577 20 qio2 G 1.129 0.121 0.164 0.460 
rs6093898 42566577 20 rad3 G 0.838 -0.176 0.091 0.053 
rs6093898 42566577 20 rage G 1.371 0.316 0.262 0.228 
rs6093898 42566577 20 rai2 G 0.715 -0.336 0.306 0.272 
rs6093898 42566577 20 rau2 G 1.265 0.235 0.208 0.258 
rs6093898 42566577 20 rde4 G 1.069 0.067 0.234 0.776 
rs6093898 42566577 20 rot4 G 0.579 -0.546 0.222 0.014 * 
rs6093898 42566577 20 twg2 G 1.131 0.123 0.089 0.167 
rs4812767 42568829 20 boma T 0.973 -0.027 0.138 0.845 
rs4812767 42568829 20 cof3 T 0.620 -0.478 0.347 0.168 
rs4812767 42568829 20 col3 T 0.901 -0.104 0.140 0.459 
rs4812767 42568829 20 edi2 T 0.924 -0.079 0.204 0.700 
rs4812767 42568829 20 gep3 T 0.889 -0.117 0.214 0.584 
rs4812767 42568829 20 grdg T 0.954 -0.047 0.163 0.774 
rs4812767 42568829 20 grnd T 0.896 -0.110 0.155 0.480 
Yanni Zeng            
 
 24 
rs4812767 42568829 20 gsk2 T 0.930 -0.073 0.122 0.549 
rs4812767 42568829 20 i2b3 T 1.098 0.093 0.122 0.444 
rs4812767 42568829 20 mmi2 T 0.968 -0.033 0.158 0.835 
rs4812767 42568829 20 mmo4 T 1.336 0.290 0.251 0.249 
rs4812767 42568829 20 nes1 T 1.047 0.046 0.092 0.619 
rs4812767 42568829 20 qi3c T 1.023 0.023 0.133 0.865 
rs4812767 42568829 20 qi6c T 1.161 0.149 0.155 0.335 
rs4812767 42568829 20 qio2 T 1.128 0.120 0.165 0.467 
rs4812767 42568829 20 rad3 T 0.827 -0.190 0.092 0.038 * 
rs4812767 42568829 20 rage T 1.371 0.316 0.262 0.228 
rs4812767 42568829 20 rai2 T 0.728 -0.317 0.306 0.300 
rs4812767 42568829 20 rau2 T 1.283 0.249 0.208 0.232 
rs4812767 42568829 20 rde4 T 1.069 0.067 0.234 0.776 
rs4812767 42568829 20 rot4 T 0.552 -0.595 0.225 0.008 * 
rs4812767 42568829 20 twg2 T 1.144 0.135 0.089 0.133 
 
Table s12 Single-SNP-based association tests for five SNPs in individual cohorts PGC2-MDD.
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rs id group OR logOR se(logOR) lower(OR) Upper(OR) p 
rs4812767 PGC_AUS 1.057 0.056 0.084 0.897 1.246 0.507 
rs4812767 PGC_GER 1.008 0.008 0.072 0.875 1.162 0.912 
rs4812767 PGC_MIXED 0.943 -0.059 0.120 0.745 1.194 0.625 
rs4812767 PGC_NET 0.955 -0.046 0.085 0.808 1.129 0.590 
rs4812767 PGC_SWE 1.144 0.135 0.089 0.960 1.363 0.133 
rs4812767 PGC_UK_IRE 0.840 -0.174 0.075 0.725 0.974 0.021* 
rs4812767 PGC_USA 1.034 0.034 0.077 0.889 1.202 0.662 
rs4812767 UKB+PGC_UK_IRE 0.938 -0.064 0.032 0.881 0.998 0.044* 
rs4812767 PGC_combined22 1.002 0.002 0.029 0.946 1.061 0.956 
rs6017218 PGC_AUS 1.016 0.016 0.070 0.886 1.166 0.817 
rs6017218 PGC_GER 1.013 0.013 0.061 0.899 1.142 0.827 
rs6017218 PGC_MIXED 1.382 0.324 0.212 0.912 2.095 0.127 
rs6017218 PGC_NET 0.770 -0.262 0.164 0.558 1.062 0.111 
rs6017218 PGC_SWE 1.092 0.088 0.076 0.941 1.268 0.248 
rs6017218 PGC_UK_IRE 0.842 -0.172 0.068 0.737 0.961 0.011* 
rs6017218 PGC_USA 1.087 0.084 0.065 0.958 1.234 0.197 
rs6017218 UKB+PGC_UK_IRE 0.928 -0.074 0.028 0.880 0.980 0.007* 
rs6017218 PGC_combined22 1.002 0.002 0.031 0.946 1.061 0.956 
rs6031242 PGC_AUS 1.016 0.016 0.075 0.877 1.177 0.835 
rs6031242 PGC_GER 1.034 0.034 0.064 0.913 1.171 0.596 
rs6031242 PGC_MIXED 1.287 0.252 0.216 0.842 1.967 0.244 
rs6031242 PGC_NET 0.652 -0.428 0.179 0.458 0.926 0.017* 
rs6031242 PGC_SWE 1.075 0.072 0.079 0.920 1.256 0.362 
rs6031242 PGC_UK_IRE 0.858 -0.153 0.071 0.747 0.987 0.032* 
rs6031242 PGC_USA 1.018 0.018 0.069 0.890 1.165 0.794 
rs6031242 UKB+PGC_UK_IRE 0.932 -0.070 0.029 0.881 0.987 0.016* 
rs6031242 PGC_combined22 0.989 -0.011 0.031 0.931 1.051 0.720 
rs6031245 PGC_AUS 1.040 0.039 0.083 0.883 1.224 0.642 
rs6031245 PGC_GER 1.012 0.012 0.072 0.878 1.166 0.872 
rs6031245 PGC_MIXED 0.949 -0.053 0.121 0.748 1.202 0.662 
rs6031245 PGC_NET 0.957 -0.044 0.085 0.810 1.131 0.607 
rs6031245 PGC_SWE 1.133 0.125 0.089 0.951 1.350 0.162 
rs6031245 PGC_UK_IRE 0.843 -0.171 0.075 0.727 0.977 0.024* 
rs6031245 PGC_USA 1.041 0.040 0.077 0.895 1.211 0.600 
rs6031245 UKB+PGC_UK_IRE 0.937 -0.066 0.032 0.880 0.997 0.040* 
rs6031245 PGC_combined22 0.991 -0.009 0.031 0.932 1.054 0.767 
rs6093898 PGC_AUS 1.064 0.062 0.084 0.903 1.254 0.460 
rs6093898 PGC_GER 0.995 -0.005 0.072 0.863 1.146 0.941 
rs6093898 PGC_MIXED 0.941 -0.061 0.120 0.743 1.191 0.611 
rs6093898 PGC_NET 0.957 -0.044 0.084 0.812 1.128 0.603 
rs6093898 PGC_SWE 1.131 0.123 0.089 0.950 1.347 0.167 
rs6093898 PGC_UK_IRE 0.848 -0.165 0.075 0.732 0.983 0.028* 
rs6093898 PGC_USA 1.042 0.041 0.077 0.897 1.211 0.589 
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rs6093898 UKB+PGC_UK_IRE 0.937 -0.065 0.032 0.881 0.998 0.042* 
rs6093898 PGC_combined22 0.991 -0.009 0.031 0.932 1.054 0.772 
Table s13 Meta-analysis results for five SNPs in groups and combined sample of PGC and all UK replication samples.
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Gene-symbol Chromosome r 
RP1-269M15.3 20 1 
PTPRT 20 0.833 
LRFN5 14 0.78 
GRM7 3 0.77 
EPHA10 1 0.746 
RP11-497E19.1 14 0.739 
RP11-586D19.1 4 0.737 
FAM78B 1 0.736 
RP11-497E19.2 14 0.736 
DLEU7 13 0.733 
C9orf91 9 0.73 
CACNA2D3 3 0.72 
FBXL2 3 0.716 
LRRC4C 11 0.716 
FAM84A 2 0.711 
RFPL1-AS1 22 0.711 
DCBLD1 6 0.709 
RFPL1 22 0.709 
CHSY3 5 0.705 
PPFIA2 12 0.704 
ARMCX2 X 0.701 
RP11-133K1.2 15 0.7 
 
Table s14.  Genes showing similar expression patterns with RP1-269M15.3 (r≥0.7) in development brain tissues in 
BRAINSPAN. r: correlation of gene expression with RP1-269M15.3. The data was downloaded from BrainSpan: 
Atlas of the Developing Human Brain [Internet]. Funded by ARRA Awards 1RC2MH089921-01, 1RC2MH090047-
01, and 1RC2MH089929-01. © 2011. Available from: http://developinghumanbrain.org.
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 28 
Gene-symbol Chromosome r 
TOX2 20 1 
GPR123 10 0.808 
KIF17 1 0.761 
CRH 8 0.754 
SYT17 16 0.748 
VWC2L 2 0.744 
ARID5B 10 0.73 
CPNE7 16 0.73 
NECAB2 16 0.719 
NTNG1 1 0.716 
STBD1 4 0.713 
CYB561 17 0.707 
FAM127A X 0.705 
RP13-137A17.4 10 0.702 
 
Table s15 Genes showing similar expression patterns with TOX2 (r≥0.7) in development brain tissues in BRAINSPAN. 
r: correlation of gene expression with TOX2. The data was downloaded from BrainSpan: Atlas of the Developing 
Human Brain [Internet]. Funded by ARRA Awards 1RC2MH089921-01, 1RC2MH090047-01, and 1RC2MH089929-
01. © 2011. Available from: http://developinghumanbrain.org 





Figure s1A Forest plots of meta-analysis of GS:SFHS, PGC2-MDD individual cohorts and UK Biobank for rs4812767. 
 
Figure s1B Forest plots of meta-analysis of GS:SFHS, PGC2-MDD individual cohorts and UK Biobank for rs6017218. 
 
 




Figure s1C Forest plots of meta-analysis of GS:SFHS, PGC2-MDD individual cohorts and UK Biobank for rs6031242.
  




Figure s1D Forest plots of meta-analysis of GS:SFHS, PGC2-MDD individual cohorts and UK Biobank for rs6031245.
  




Figure s1E Forest plots of meta-analysis of GS:SFHS, PGC2-MDD individual cohorts and UK Biobank for rs6093898




Figure s2a Functional annotation for RP1-269M15.3. 
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Single-SNP-based-genome-wide analyses such as GWAS have been shown to be 
under powered for MDD. As an alternative approach, HRHM targets the combined 
effects from multiple SNPs within haplotype blocks. Using this method and a large 
Scottish sample we identified a 24kb region within TOX2 gene significantly 
associated with MDD and this signal was further located to single SNPs with 
potentially functional effects by association tests. The results were replicated in 
independent samples.  
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